NRx Pharmaceuticals reported a quarterly loss of $0.04 per share, beating the Zacks Consensus Estimate for a loss of $0.05 and improving sharply from a $0.34 loss per share a year ago. The narrower loss suggests better operating performance and modestly improved fundamentals, though the company remains unprofitable.
NRx Pharmaceuticals reported a quarterly loss of $0.04 per share, beating the Zacks Consensus Estimate for a loss of $0.05 and improving sharply from a $0.34 loss per share a year ago. The narrower loss suggests better operating performance and modestly improved fundamentals, though the company remains unprofitable.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
